• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

On heels of Mar­i­Tide da­ta, Dan­ish obe­si­ty biotech dis­clos­es €80M Se­ries A

5 months ago
Financing
Startups

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

5 months ago
Pharma
FDA+

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

5 months ago
R&D
Pharma

SEC and Kiromic set­tle over biotech's fail­ure to dis­close clin­i­cal tri­al holds ahead of stock of­fer­ing

5 months ago
Pharma
Law

Eli Lil­ly, Pfiz­er stress in­de­pen­dence of tele­health part­ners in re­sponse to sen­a­tors

5 months ago
Pharma
FDA+

Ap­plied Ther­a­peu­tics gets FDA warn­ing let­ter over study of re­ject­ed rare dis­ease drug

5 months ago
FDA+

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

5 months ago
Deals
Pharma

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

5 months ago
Deals
R&D

Re­lay li­cens­es can­cer drug to Ko­re­an biotech for $75M

5 months ago
Deals

Carte­sian tees up Phase 3 mR­NA CAR-T study in myas­the­nia gravis

5 months ago
R&D

BMS inks deal with AI Pro­teins; Terns’ ear­ly-stage leukemia da­ta

5 months ago
News Briefing

Roivant says long-shot drug for a rare lung dis­ease failed its Phase 2 study

5 months ago
R&D

Af­ter deal about-face and a spin­out, Maze as­sem­bles $115M Se­ries D

5 months ago
Financing
Startups

Take­da to pay $200M for rights to ane­mia drug from Keros

5 months ago
Deals
Pharma

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

5 months ago
Startups
Deals

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

5 months ago
Financing
R&D

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

5 months ago
Deals
Pharma

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

5 months ago
R&D

FDA de­fends in­creased use of guid­ance in new re­port to Con­gress

5 months ago
FDA+

Sanofi ear­marks €1B for new in­sulin pro­duc­tion fac­to­ry in Bei­jing   

5 months ago
China
Manufacturing

J&J looks to ex­pand Trem­fya in two pe­di­atric in­di­ca­tions

5 months ago
Pharma
FDA+

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

5 months ago
People
FDA+

Bio­con lands FDA ap­proval for an­oth­er Ste­lara biosim­i­lar

5 months ago
Pharma
FDA+

Ole­ma, No­var­tis ink an­oth­er agree­ment, this time for a late-stage breast can­cer tri­al

5 months ago
Deals
R&D
First page Previous page 58596061626364 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.